The global cerebrospinal fluid (CSF) management market is expected to reach USD 1.56 billion by 2022 from USD 1.26 billion in 2017, at a CAGR of 4.4 percent. The key factors driving the growth of this market include the high prevalence of hydrocephalus and the subsequent increase in the number of shunting procedures and the growing geriatric population.
In 2017, the shunts segment accounted for the largest share of the global market. The large share of this segment can be primarily attributed to growing number of shunting procedures performed worldwide as well as the increasing number of revision shunt surgeries owing to shunt malfunction and infection. In 2017, the pediatric segment held the largest share of the global market. The large share of this segment can be primarily attributed to high prevalence of congenital hydrocephalus along with the rising number of shunting procedures in the pediatric population.
In 2017, North America held the largest share of the cerebrospinal fluid (CSF) management market, followed by Europe. Factors such as the rising prevalence of hydrocephalus, increasing funding for hydrocephalus research in the US, and the launch of Hydrocephalus Canada are contributing to the dominant share of this region. The key players in the global cerebrospinal fluid (CSF) management market are Medtronic (Ireland), Integra (US), B. Braun (Germany), DePuy Synthes (US), Spiegelberg GmbH & Co. KG (Germany), SOPHYSA (France), Natus Medical Incorporated (US), Dispomedica GmbH (Germany), Delta Surgical Limited (UK), Argi Grup (Turkey), Moller Medical GmbH (Germany), G. SURGIWEAR LTD. (India), and Wellong Instruments Co., Ltd. (Taiwan). – MarketsandMarkets